Information:
Fel:
ID
19753
Beskrivning
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT00389285
Länk
https://clinicaltrials.gov/show/NCT00389285
Nyckelord
Versioner (1)
- 2017-01-26 2017-01-26 -
Uppladdad den
26 januari 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Carcinoma, Renal Cell NCT00389285
Eligibility Carcinoma, Renal Cell NCT00389285
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Renal Cell NCT00389285
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Conventional (Clear Cell) Renal Cell Carcinoma
Item
diagnosis of rcc of predominantly clear cell histology
boolean
C0279702 (UMLS CUI [1])
Therapeutic procedure Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
either no prior treatment or a maximum of 2 prior treatment regimens for metastatic rcc that included no more than 1 treatment regimen targeting the vascular endothelial growth factor (vegf) pathway (phase 1 only)
boolean
C0087111 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
systemic therapy Quantity Metastatic Renal Cell Cancer | Therapeutic procedure Targeting VEGF Signaling Pathway
Item
at least 1 but no more than 2 prior systemic therapies for metastatic rcc that included no more than 1 therapy targeting the vegf pathway (phase 2 only)
boolean
C1515119 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
C1265611 (UMLS CUI [1,2])
C0278678 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C2984329 (UMLS CUI [2,3])
Measurable Disease
Item
disease measurable per the response evaluation criteria in solid tumors (recist) (phase 2 only)
boolean
C1513041 (UMLS CUI [1])
Communicable Disease | Systemic disease Significant
Item
presence of acute infection or other significant systemic illness
boolean
C0009450 (UMLS CUI [1])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
C0442893 (UMLS CUI [2,1])
C0750502 (UMLS CUI [2,2])
Central Nervous System Involvement
Item
central nervous system involvement by malignancy
boolean
C4050309 (UMLS CUI [1])
Malignant Neoplasms
Item
history of other cancer within 5 years
boolean
C0006826 (UMLS CUI [1])
rIL-21 | sorafenib
Item
previously received ril-21 or sorafenib
boolean
C1831593 (UMLS CUI [1])
C1516119 (UMLS CUI [2])
C1516119 (UMLS CUI [2])